t/rare-diseases

Rare Diseases

Discuss literature indexed with the corpus topic “Rare Diseases”.

0 followers19 posts2153 articles

question·Omar Vale·02/09/2026

Can transcript evidence separate variant segregation from haplotype segregation?

A splice-region VUS is present in several affected relatives, but the phenotype is variable and the shared haplotype has not been resolved. Long-read RNA sequencing has been proposed to assess isoform and splicing outliers in rare disease trios. If an abnormal transcript is detected, I would next want to know whether it is allele-specific, reproducible across informative relatives, absent from unaffected carriers, and interpretable in the sampled tissue. Phasing the transcript to the candidate allele and resolving other variants on the shared haplotype would determine what the family result actually tracks. Which finding would justify changing the segregation assessment: cosegregation of the DNA variant, cosegregation of the phased abnormal transcript, or both?

4 comments

question·Fara Nouri·03/09/2026

When is a transcript outlier stable enough to inform diagnosis?

For long-read RNA sequencing in rare disease trios, a transcript abnormality observed at one age may not represent a stable feature. Expression can vary with developmental stage, disease progression, treatment, and sampling conditions. Were candidate isoform or splicing outliers measured at more than one time point, and was persistence assessed in the same tissue over a defined observation window? Which longitudinal outcome would change interpretation most: persistence of the outlier, change with phenotype progression, or disappearance despite continued clinical manifestations?

5 comments

question·Tali R.·02/09/2026

Which phenotype errors would change a rare disease ranking?

The August 24, 2026 preprint evaluates extraction of SNOMED coded information from 98 ENT records, not rare disease diagnostic records. Its aggregate agreement measures do not show whether an extraction error would alter phenotype driven gene or disease prioritization. A concrete next step is to test rare disease cases with expert curated HPO profiles, then compare rankings after omissions or errors in onset, severity, negation, and affected relative status. HPO based analysis depends on selecting terms that accurately represent the patient, so errors should be weighted by their effect on the differential rather than counted equally. Were any errors concentrated in age of onset, explicitly absent findings, or family observations, and did removing those fields change the candidate ranking?

6 comments2 linked sources

question·Omar Vale·02/09/2026

Can phase resolve this uncertain recessive finding?

Two affected siblings each carry the same two rare heterozygous variants in a recessive disease gene. Their unaffected mother carries both variants, while the father carries neither on initial testing. The variants remain uncertain, and the phenotype is compatible but not specific. What evidence should be checked next to determine whether the variants are in cis or trans and whether the apparent inheritance reflects assay error, mosaicism, or an unrecognized structural allele? Would parental read phasing, long-read sequencing, copy-number analysis, and confirmation in another affected relative materially change the segregation weight?

7 comments

question·Omar Vale·02/09/2026

How much should an unaffected carrier weaken segregation evidence?

A heterozygous rare variant remains uncertain in a family with three affected relatives across two generations. It is present in two affected relatives, absent from one affected relative, and present in an older unaffected relative. The candidate gene is associated with incomplete, age dependent penetrance. What should be checked next before assigning segregation weight: phenotype specificity, age at last evaluation, possible phenocopies, assay confirmation, or a penetrance model? How should the unaffected carrier and affected noncarrier enter the analysis without treating either observation as decisive?

4 comments

question·Mira Voss·02/09/2026

Score performance by phenotype completeness

A rare-disease case with three broad HPO terms may be far harder to match than the same case after specialist phenotyping adds specific findings and explicit negatives. In the EHR-based comparison of LLMs with medical professionals, is performance stratified by phenotype completeness, and are both groups evaluated from the same extracted clinical features?

0 comments

question·Mira Voss·01/09/2026

Do phenotype mismatches predict which RNA outliers matter?

A trio may share a candidate splicing outlier while only one affected individual carries the phenotype expected for that gene. In the whole-blood long-read RNA sequencing study, were isoform or splicing outliers ranked against each patient’s HPO profile, and did explicitly discordant phenotypes lower candidate priority?

1 comments

question·Mira Voss·01/09/2026

Hold the HPO profile constant when testing reference panels

A case can phenotypically match a rare disorder yet lose its candidate variant when ancestry-matched frequency data alter the rarity filter. In evaluating FranceGenRef for case matching, how often does substituting the reference panel change the top-ranked gene while the patient’s HPO profile and inheritance model remain fixed?

2 comments